New Enterprise Associates related stories
All articles and analysis
Will the Rally Continue?Seven more VC-backed companies went public in April, but none made it out as of mid-May
Playing the Flash CardWith flash memory prices declining, VCs are wagering the technology will be a major force in data centers and the enterprise
VC Still Blowing Into Wind PowerThe wind power industry is mature, but it is attracting more venture investment than other alternative energy sectors, as VCs see opportunities for continued technological advances
Keep on Rockin’ in the Venture WorldNorwest’s Tim Chang and Mayfield’s Raj Kapoor are part of the latest rock band to hit the venture business
Booyah banks $20M from Accel, othersGame startup has now raised $29.5M in VC funding
- peHUB Wire: Thursday, May 27, 2010
Random Ramblings
- peHUB Wire: Thursday, May 27, 2010
Random Ramblings
- Tesaro Raises $60 Million in Series A Funding
Tesaro Inc., a Boston-based oncology pharma startup, has secured $60 million in Series A commitments led by New Enterprise Associates. The round includes an initial $20 million calldown and $40 million in capital reserves. Tesaro was founded by former executives with MGI Pharma, which was acquired by Eisai Co. in 2008 for $3.9 billion.
- Clovis Oncology Signs $209 Million R&D Deal with Avila Therapeutics
Clovis Oncology has signed a development and commercialization agreement for Avila Therapeutics' epidermal growth factor receptor (EGFR) mutant-selective inhibitor (EMSI) program, which is in pre-clinical development for the treatment of non-small cell lung cancer. Avila will receive up to $209 million in up-front and clinical milestone payments, plus possible royalty and sub-licensing fees. Clovis Oncology last year raised $146 million in Series A funding from Domain Associates, New Enterprise Associates, Versant Ventures, Aberdare Ventures, Abingworth, Frazier Healthcare Ventures and ProQuest Investments. Avila Therapeutics has raised over $51 million from The Novartis Option Fund, Abingworth Management, Advent Venture Partners, Atlas Venture and Polaris Venture Partners.
- Clovis Oncology Signs $209 Million R&D Deal with Avila Therapeutics
Clovis Oncology has signed a development and commercialization agreement for Avila Therapeutics' epidermal growth factor receptor (EGFR) mutant-selective inhibitor (EMSI) program, which is in pre-clinical development for the treatment of non-small cell lung cancer. Avila will receive up to $209 million in up-front and clinical milestone payments, plus possible royalty and sub-licensing fees. Clovis Oncology last year raised $146 million in Series A funding from Domain Associates, New Enterprise Associates, Versant Ventures, Aberdare Ventures, Abingworth, Frazier Healthcare Ventures and ProQuest Investments. Avila Therapeutics has raised over $51 million from The Novartis Option Fund, Abingworth Management, Advent Venture Partners, Atlas Venture and Polaris Venture Partners.